Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer-Reference-Cited by-同舟云学术

Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer

Published:2024-07-26 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Sharma Shikha^ORCID,Carey Niamh,McConnell David,Lowery Maeve,O’Sullivan Jacintha,McCullagh Laura,

Funder

Enterprise Ireland

University of Dublin, Trinity College

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01413-8.pdf

Reference69 articles.

1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38.

2. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.

3. National Cancer Institute. Stomach cancer survival rates and prognosis. United States 2023. https://www.cancer.gov/types/stomach/survival#:~:text=Stomach%20Cancer%20Statistics&text=The%205%2Dyear%20relative%20survival%20rates%20for%20different%20stages%20of,nearby%20lymph%20nodes%20or%20organs. Accessed 21 Apr 2023.

4. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up☆. Ann Oncol. 2022;33(10):1005–20.

5. U.S. Food & drug administration. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer 2021. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer?utm_medium=email&utm_source=govdelivery. Accessed 27 Apr 2023.